About LAVA Therapeutics N.V.
https://www.lavatherapeutics.comLAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
CEO
Stephen Allen Hurly
Compensation Summary
(Year 2024)
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
SHAY CAPITAL LLC
Shares:2.55M
Value:$4.43M
REDMILE GROUP, LLC
Shares:2.07M
Value:$3.61M
BML CAPITAL MANAGEMENT, LLC
Shares:1.97M
Value:$3.43M
Summary
Showing Top 3 of 23
About LAVA Therapeutics N.V.
https://www.lavatherapeutics.comLAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $7.55M ▲ | $-7.19M ▲ | 0% | $-0.27 ▲ | $-7.18M ▲ |
| Q2-2025 | $0 | $7.29M ▼ | $-8.64M ▼ | 0% | $-0.32 ▼ | $-8.56M ▼ |
| Q1-2025 | $0 ▼ | $7.59M ▲ | $-3.48M ▲ | 0% ▲ | $-0.13 ▲ | $-3.02M ▲ |
| Q4-2024 | $4.99M ▲ | $-12.46M ▼ | $-3.97M ▲ | -79.56% ▼ | $-0.14 ▲ | $-3.11M ▲ |
| Q3-2024 | $0 | $11.29M | $-12.3M | 0% | $-0.46 | $-10.86M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $49.66M ▼ | $51.91M ▼ | $39.23M ▼ | $12.68M ▼ |
| Q2-2025 | $56.17M ▼ | $60.55M ▼ | $40.61M ▼ | $19.93M ▼ |
| Q1-2025 | $66.56M ▼ | $71.16M ▼ | $45.37M ▼ | $25.78M ▼ |
| Q4-2024 | $76.58M ▼ | $80.83M ▼ | $53.09M ▲ | $27.75M ▼ |
| Q3-2024 | $78.88M | $83.36M | $50.36M | $32.99M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.19M ▲ | $-4.87M ▲ | $27.7M ▲ | $0 | $23.28M ▲ | $-4.87M ▲ |
| Q2-2025 | $-8.64M ▼ | $-13.75M ▼ | $-2.5M ▼ | $0 | $-13.29M ▼ | $-13.75M ▼ |
| Q1-2025 | $-3.48M ▲ | $-11.64M ▼ | $15.16M ▲ | $0 ▲ | $4.66M ▼ | $-11.64M ▼ |
| Q4-2024 | $-4.22M ▲ | $-1.41M ▲ | $10.97M ▲ | $-206K ▲ | $8.05M ▲ | $-1.41M ▲ |
| Q3-2024 | $-12.2M | $-8.63M | $447K | $-368K | $-8.12M | $-8.65M |
CEO
Stephen Allen Hurly
Compensation Summary
(Year 2024)
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
SHAY CAPITAL LLC
Shares:2.55M
Value:$4.43M
REDMILE GROUP, LLC
Shares:2.07M
Value:$3.61M
BML CAPITAL MANAGEMENT, LLC
Shares:1.97M
Value:$3.43M
Summary
Showing Top 3 of 23